{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:54:59Z","timestamp":1776426899217,"version":"3.51.2"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,5,25]],"date-time":"2014-05-25T00:00:00Z","timestamp":1400976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p><jats:italic>Helicobacter pylori<\/jats:italic> infection occurs in children and adults worldwide. Standard triple therapy of omeprazole, amoxicillin and clarithromycin (OAC) may not be optimal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate quadruple therapy with bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, given with omeprazole in <jats:italic>H. pylori<\/jats:italic> infected subjects who failed previous OAC eradication therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a multicenter, open\u2010label, single\u2010arm, multinational study. <jats:italic>Helicobacter pylori<\/jats:italic>\u2010positive subjects who had failed \u22651 previous course of OAC therapy with or without up to three supplemental treatments in the previous year. Subjects were treated for 10\u00a0days with a combination formulation containing bismuth subcitrate potassium 140\u00a0mg, tetracycline hydrochloride 125\u00a0mg, and metronidazole 125\u00a0mg, three capsules four times daily (q.d.s.), and omeprazole 20\u00a0mg twice daily (b.d.). The primary endpoint was <jats:italic>H. pylori<\/jats:italic> eradication rate defined as one negative <jats:sup>13<\/jats:sup>C\u2010urea breath test \u226528\u00a0days post\u2010treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:italic>Helicobacter pylori<\/jats:italic> eradication rates ranged from 93.2% to 93.8% in the intent\u2010to\u2010treat population (<jats:italic>n<\/jats:italic>\u00a0=\u00a049), and from 94.7% to 95.0% in the PP population (<jats:italic>n<\/jats:italic>\u00a0=\u00a040). No clinically meaningful differences were observed when analysed by country. Metronidazole resistance was observed in 16\/49 (32.7%) subjects and clarithromycin resistance in 31\/49 (63.3%) subjects. Thirty\u2010three subjects (67.3%) reported 87 adverse events, and only one (2%) discontinued the study for an adverse event.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A quadruple regimen of bismuth, metronidazole and tetracycline plus omeprazole produces a high eradication rate in subjects previously failing <jats:italic>H. pylori<\/jats:italic> eradication regimens. This bismuth\u2010based regimen offers an effective option as rescue therapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.12808","type":"journal-article","created":{"date-parts":[[2014,5,26]],"date-time":"2014-05-26T03:54:42Z","timestamp":1401076482000},"page":"171-177","source":"Crossref","is-referenced-by-count":78,"title":["Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of <i>Helicobacter pylori<\/i>"],"prefix":"10.1111","volume":"40","author":[{"given":"J. C.","family":"Delchier","sequence":"first","affiliation":[{"name":"Gastroenterology Unit Albert Chenevier\u2010Henri Mondor Hospital AP\u2010HP UPEC Universit\u00e9 Paris 12 Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Malfertheiner","sequence":"additional","affiliation":[{"name":"Klinic fur Gastroenterologie, Hepatologie, and Infektiologie Otto\u2010v.\u2010Guerike Universitat Magdeburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Thieroff\u2010Ekerdt","sequence":"additional","affiliation":[{"name":"Aptalis U.S., Inc. Bridgewater NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,5,25]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"299","article-title":"Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline","volume":"20","author":"Hunt RH","year":"2011","journal-title":"J Gastrointest Liver Dis"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.12.036"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302084"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302254"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3283643491"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318247177e"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v4.i3.43"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.192757"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.t01-1-07288.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60020-2"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01393.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.05982.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.508"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000350719"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.22163000.x"},{"key":"e_1_2_7_17_1","first-page":"391","article-title":"Bismuth toxicity in man II. Review of bismuth blood and urine levels in patients after administration of therapeutic bismuth formulations in relation to the problem of bismuth toxicity in man","volume":"26","author":"Serfontein WJ","year":"1979","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004265643"},{"key":"e_1_2_7_19_1","first-page":"16","article-title":"The use of bismuth in gastroenterology. The ACG Committee on FDA\u2010Related Matters. American College of Gastroenterology","volume":"86","author":"Marshall BJ","year":"1991","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.7361"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03386.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/723183"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-13-138"},{"key":"e_1_2_7_24_1","first-page":"273","article-title":"Doxycycline\u2010based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open\u2010label control study in Chinese patients","volume":"53","author":"Wang Z","year":"2012","journal-title":"Singapore Med J"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2009.00735.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2900-x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2012.00962.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2011.00857.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.12808","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.12808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:21:59Z","timestamp":1695572519000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.12808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,25]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/apt.12808"],"URL":"https:\/\/doi.org\/10.1111\/apt.12808","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,25]]}}}